Ownership and insider activity for Precision BioSciences, Inc. (DTIL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
Price
| Price | $6.63 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-01 | Gorsuch Cassandra Louise | |||
| 2026-08-01 | Gorsuch Cassandra Louise | 235 | $8K | |
| 2026-08-01 | Gorsuch Cassandra Louise | 585 | $210K | |
| 2026-08-01 | Gorsuch Cassandra Louise | 179,340 | ||
| 2026-08-01 | Burris Mei Zhang Lu | |||
| 2026-08-01 | Burris Mei Zhang Lu | 945 | $357K | |
| 2026-08-01 | Burris Mei Zhang Lu | 214 | $37K | |
| 2026-08-01 | Burris Mei Zhang Lu | 403 | $137K | |
| 2026-08-01 | Burris Mei Zhang Lu | 778 | $95K | |
| 2026-08-01 | Burris Mei Zhang Lu | 30,129 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.4M | $62.8M | $103.2M | $180.9M | $89.8M | $143.7M | $189.6M | $116.7M | $85.9M | $110.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $413000 | $4.8M |
| Receivables | $386000 | $22000 | $523000 | $965000 | $10.0M | $488000 | $720000 | $12.8M | $1.7M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $94.4M | $64.3M | $115.7M | $193.7M | $105.6M | $161.8M | $199.1M | $136.4M | $95.0M | $118.7M |
| Property, Plant & Equipment | $3.5M | $8.1M | $21.1M | $39.6M | $41.5M | $29.3M | $13.8M | $14.6M | $10.2M | $7.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $90000 | $1.5M | $1.4M | $1.4M | $2.0M | $731000 | $400000 | $622000 | $1.2M |
| Total Assets | $98.4M | $72.7M | $138.6M | $235.2M | $150.2M | $211.5M | $238.2M | $159.8M | $136.4M | $154.4M |
| Accounts Payable | $1.3M | $1.8M | $2.2M | $2.0M | $792000 | $1.1M | $653000 | $3.0M | $1.3M | $296000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $22.4M | 0 | 0 |
| Total Current Liabilities | $8.3M | $9.2M | $14.1M | $26.9M | $42.8M | $36.0M | $59.7M | $50.0M | $15.0M | $8.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $2.5M | $22.2M | 0 | $22.3M | $22.4M |
| Total Liabilities | $103.2M | $99.1M | $98.6M | $96.9M | $105.7M | $120.3M | $177.7M | $140.9M | $80.0M | $62.2M |
| Retained Earnings | -$18.0M | -$39.1M | -$85.2M | -$177.1M | -$286.1M | -$316.7M | -$428.3M | -$489.6M | -$482.5M | -$528.2M |
| Total Equity | -$4.7M | -$26.4M | $40.0M | $138.3M | $44.4M | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
| Total Debt | 0 | 0 | 0 | 0 | $10.5M | $9.1M | $25.0M | $31.3M | $30.0M | $28.8M |
| Net Debt | -$93.4M | -$62.8M | -$103.2M | -$180.9M | -$79.3M | -$134.6M | -$164.6M | -$85.4M | -$56.3M | -$86.8M |
| Working Capital | $86.1M | $55.1M | $101.6M | $166.7M | $62.7M | $125.8M | $139.4M | $86.4M | $80.0M | $109.8M |
Financial Health
| Debt / Equity | 0.62 |
| Current Ratio | 12.82 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.31 |
Profitability
| Return on Equity | -91.60% |
| Return on Invested Capital | -30.23% |
| Return on Assets | -41.88% |
| Gross Margin | 100.00% |
| Operating Margin | -80.78% |
| Net Margin | -117.04% |
Related companies: ABOS · ALEC · GOSS · HOOK · HRTX · KLDO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of DTIL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks